Are ultrasensitive ctDNA assays ready for clinical use in early-stage NSCLC?
{{output}}
Disease recurrence in early-stage non-small cell lung cancer (NSCLC) remains a persistent clinical challenge, underscoring the need for better prognostic biomarkers. In this preview, we highlight the clinical implications of ultrasensitive ctDNA monitoring in ... ...
